On Monday, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares inclined 0.71% to $0.240.
Aeterna Zentaris Inc. (AEZS) declared it has reached its aim of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The trial is being conducted in over 120 sites in North America, Europe and Israel. The primary efficacy endpoint is improvement in overall survival.
Following its first pre‑specified interim analysis last April, a Data and Safety Monitoring Board recommended that the ZoptEC Phase 3 study continue as planned. A second interim analysis is predictable during Q4, 2015 at about 192 events, with the final analysis planned at an anticipated 384 events. The trial is predictable to be accomplished by the end of 2016.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Maxim Integrated Products Inc. (NASDAQ:MXIM)’s shares dropped -0.43% to $32.13.
Maxim Integrated Products, Inc. (MXIM) will declare fiscal fourth quarter 2015 results after market close on Thursday, July 23, 2015. The full release will be accessible at www.maximintegrated.com/company/investor.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. It primarily serves automotive, communications and data center, computing, consumer, and industrial markets.
At the end of Monday’s trade, Synthetic Biologics Inc ( NYSEMKT:SYN)‘s shares surged 14.14% to $3.47.
Synthetic Biologics, Inc. (SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, stated the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
American Express Company (NYSE:AXP), ended its Monday’s trading session with 1.59% gain, and closed at $78.54.
American Express Company (AXP) declared the launch of Amex Express Checkout, a first-ever, fast and secure way for U.S. Card Members to check out quickly at participating online merchants by using their americanexpress.com account login. With Amex Express Checkout, Card Members simply use their existing americanexpress.com User ID and Password, and American Express auto-fills the checkout fields with their American Express® Card details and relevant account information in just a few clicks. Unlike other online payments tools presently in the marketplace, Amex Express Checkout is not a wallet, and does not require a Card Member to create or manage a new account.
Amex Express Checkout is accessible for Card Members to use online recently at BarkBox, Burberry, Ledbury, Newegg, Sabon, Ticketmaster, Warby Parker and The Wall Street Journal. American Express and Stripe are working together to allow merchants using Stripe as a payments platform to easily enable Amex Express Checkout for their customers. And, Amex Express Checkout is predictable to be accessible in the coming months on websites for Avis Car Rental, Banana Republic, Cole Haan, Hulu, Gap, Intermix, Old Navy, POPSUGAR Must Have, Rocketmiles, 1-800-FLOWERS.COM and others.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide. The company operates through four segments: U.S. Card Services, International Card Services, Global Commercial Services, and Global Network & Merchant Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
